Empower Clinics To Tap $77 BILLION CRO Market With Partnership To Launch US Clinical Trial Services. Revenues Expected To Commence “Quickly”

Empower $EPW $EPWCF is an integrated healthcare company - serving patients through medical centers, a medical device company and a high complexity medical diagnostics laboratory. More than just lip service, here are their latest financial results:

2021 Annual Revenue $4.37M - Up 355% vs 2020

• 2021 Annual Revenue $4.37M Up 355% vs 2020
• Q1-22 Revenue $1,106,950 Gross margin 21%
• Q2-22 Revenue $1,553,980 Gross margin 47%
• Q3-22 Revenue $1,573,809 Gross margin 59%

BUILDING A SCALABLE, INTEGRATED HEALTHCARE COMPANY.

$EPW is generating these results from an ecosystem of medical divisions across North America that are both complementary and forming the basis of a much larger expansion into the US market, as follows:

• Medisure Laboratory - High complexity lab providing diagnostic and testing services
• MediSure Canada - A leading At-home diagnostics testing & medical device company
• The Medi-Collective - Clinics providing multi-disciplinary group of medical practitioners

LETTER OF INTENT TO LAUNCH US CLINICAL TRIAL MANAGEMENT SERVICES FOR BIOTECH AND PHARMACEUTICAL INDUSTRIES

If preparation is the key to success, then the building of a scalable, integrated healthcare company over the last 3 years is precisely the reason for this major announcement earlier this week Signed Letter of Intent for Partnership to Launch US Clinical Trial Management Services for Biotech and Pharmaceutical Industries.

The partnership with renowned Dr. Mocherla will leverage the $EPW lab in Dallas to serve the clinical trials market. Specifically, the partnership

$USD 76 BILLION MARKET OPPORTUNITY GROWING TO $127 BILLION BY 2028

To say the market for helping the biggest pharmaceutical and biotech companies in the world run clinical trials is massive is an understatement. The CRO Services Market is estimated to be worth $76.6 billion in 2023 and poised to reach $127.3 billion by 2028, growing at a CAGR of 10.7% according to a new report by MarketsandMarkets.

If you’re wondering how long it might take for the partnership to crack this nut, CEO McAuley during our interview stated he expects to get to revenues “quick”.

JOINT VENTURE TERMS SUPPORT CEO EXPECTATION OF “GETTING TO REVENUES QUICK”

We’ve all seen our share of Joint Ventures in which companies are actually looking to throw spaghetti at the wall and see what sticks. But the terms of this JV indicate the partners are very serious and have high expectations:

• $US 200,00 Seed Capital Contributed By Each Partner To The JV
• 2 Million Shares Of $EPW Issued To Dr. Mocherla.
• Upon Achieving $US 5M Revenue, $EPW To Grant 750,000 Stock Options To Mocherla

What did Steven McAuley, Chairman and CEO of Empower have to say?

"This is a transformational partnership for Empower Clinics. Despite the global economic headwinds, the pharmaceutical and biotech industries continue to see strong growth and investment in R&D. Our diagnostics laboratory in Dallas serves as the perfect hub to launch US SMO services with the guidance of Dr. Mocherla. From there we can continue to launch additional SMO sites throughout US and Canada by leveraging Empower's network of health professionals and our unique access to capital markets as a public company.